Hematology Frontier

In recent years, the field of hematologic oncology has experienced remarkable breakthroughs, with significant advancements in mantle cell lymphoma (MCL). Chinese researchers have increasingly contributed to this progress, playing a pivotal role in driving academic development and clinical practice in the field. As we step into the new year, Hematology Frontier invited Professor Shuhua Yi from the Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences, to review the major events and breakthroughs in MCL during 2024. This comprehensive summary aims to provide valuable insights for clinical practice and future research directions.

From November 14 to 17, 2024, the Cellular Therapy and Immunotherapy Conference (CTI) took place in Hangzhou, China, attracting top experts, scholars, and industry leaders in the fields of cell…

From November 14 to 17, 2024, the Cellular Therapy and Immunotherapy Conference (CTI) was held in Hangzhou, China, bringing together global leaders in cell and immunotherapy. This conference served as…

From November 14 to 17, 2024, the Cellular Therapy and Immunotherapy Conference (CTI) was held in Hangzhou, China, bringing together leading experts, scholars, and industry leaders in the fields of…

From November 14 to 17, 2024, the Cellular Therapy and Immunotherapy Conference (CTI) was held in Hangzhou, China. The event gathered top experts, scholars, and industry leaders in cellular and…

The 66th American Society of Hematology (ASH) Annual Meeting was held from December 7–10, 2024, in San Diego, USA. As one of the world's largest international academic conferences in the field of hematology, ASH brings together cutting-edge research and the latest drug development data, showcasing the highest level of global hematology research. During this event, Dr. Kai Hu, Director of the Lymphoma and Myeloma Department at Beijing GoBroad Boren Hospital, had multiple studies (abstracts 3079, 3387, and 1745) selected for presentation, focusing on CAR-T therapy in lymphoma and myeloma. Oncology Frontier – Hematology Frontier invited Professor Hu to share in-depth insights and analyses on these studies

The 66th American Society of Hematology (ASH) Annual Meeting was held from December 7–10, 2024, in San Diego, USA. As one of the largest global academic events in hematology, it showcased cutting-edge research and the latest drug development data. At this prestigious conference, Dr. Zhihui Li from Beijing GoBroad Boren Hospital (Dr. Tong Wu ’s team) presented an oral abstract (Abstract 599) investigating the efficacy of allogeneic hematopoietic stem cell transplantation (allo-HSCT) in advanced natural killer/T-cell lymphoma (NKTCL) and analyzing prognostic factors affecting transplantation outcomes. Hematology Frontier  invited Professor Li to provide in-depth insights into this study.

The 66th Annual Meeting of the American Society of Hematology (ASH) was held from December 7 to 10, 2024, in San Diego, USA. This global event brought together leading experts in hematology to discuss the latest advancements in the field. At the meeting, the team led by Dr. Ruidong Zhang from Beijing Children’s Hospital，Capital Medical University presented significant findings (Abstract O312) on the treatment of pediatric B-cell acute lymphoblastic leukemia (B-ALL), providing fresh insights and possibilities for future therapies. Hematology Frontier invited Dr. Peijing Qi, the study's lead investigator, to provide an in-depth analysis of the research and its implications for clinical practice.

The 66th American Society of Hematology (ASH) Annual Meeting, held in San Diego from December 7–10, 2024, brought together global hematology experts to discuss the latest research advancements. Among the noteworthy contributions, Dr. Qingxiao Song’s team from the Hematology Medical Center of The Second Affiliated Hospital of Army Medical University (Xinqiao Hospital) had three studies selected (O263, P3391, P4777), with two of them earning ASH Abstract Achievement Awards. These studies offer new insights and therapeutic possibilities for chronic graft-versus-host disease (cGVHD). Hematology Frontier invited Dr. Qingxiao Song for an in-depth analysis of these groundbreaking studies.

The 66th American Society of Hematology (ASH) Annual Meeting concluded successfully from December 7 to 10, 2024, in San Diego, USA. As the largest and most comprehensive international academic conference in the field of hematology, ASH attracts numerous experts and scholars worldwide to discuss groundbreaking research and advancements in hematology.At this year’s ASH meeting, the team led by Dr. Bing Xu and Dr. Zhijuan Lin from The First Affiliated Hospital of Xiamen University presented multiple studies, including one oral presentation. Their research covered various topics such as the immune microenvironment of Epstein-Barr Virus-positive diffuse large B-cell lymphoma (EBV+DLBCL), the prognostic relevance of SUVmax in follicular lymphoma (FL), and immune microenvironmental changes in FL patients with early progression. Hematology Frontier had the privilege of interviewing Professor Zhijuan Lin on-site to discuss her team's findings and the latest significant developments in FL research presented at the conference.